|
|
7651 Anagram Drive
Eden Prairie, MN 55344 USA
phone:(952) 345-4201
fax:(952) 224-0181
|
|
| Symbol |
SHC |
| Exchange |
ASX |
| Founded |
2000 |
| Employees |
13 |
|
|
| www.sunshineheart.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Implantable Cardiac Assist Device for Patients with Heart Failure |
|
| Management |
| David Rosa
CHIEF EXECUTIVE OFFICER; BOARD OF DIRECTORS
William Peters, MD
MEDICAL DIRECTOR & CHIEF TECHNICAL OFFICER; BOARD OF DIRECTORS
Debra Kridner
VICE PRESIDENT CLINICAL RESEARCH AND REGULATORY AFFAIRS
Kevin Bassett
VICE PRESIDENT RESEARCH, DEVELOPMENT AND QUALITY ASSURANCE |
| |
|
|
|
|
|
|
|
| Keywords |
| device, peri-aortic, counterpulsation, devices, extra-aortic, eab, Cardiology, cardiac, heart, heart, blood, cardio, Australia |
|
|
|
| Description |
|
Sunshine Heart is a medical device company that develops cardiac assist devices to treat patients with moderate to severe long term heart failure. |
|
| Products / Services |
The Sunshine Heart C-Pulse is a pliable, inflatable cuff implanted in the patient and wrapped around the patient's ascending aorta before being attaching the sensing lead to the heart. It is designed to increase coronary blood flow and improve patient quality of life, as well as to provide immediate and sustained symptom relief.
|
|
| Technology / Differentiation |
| Through the use of counterpulsation technology, C-Pulse is designed to increase cardiac output while reducing the heart's workload for ventricular loading. The less invasive non-blood contacting feature of the device make the C-Pulse unique, as it augments the heart's function while reducing risks such as bleeding and stroke. The device can be turned off and detached safely. In failure modes, C-Pulse is considered to have an associated low risk of death or disability. |
|
| Market / Customers |
C-Pulse is uniquely positioned to fulfill the unmet clinical need between CRT Pacemakers and end stage therapies, a market worth over $1 billion annually. The simple, safe, straight-forward and cost-effective implant procedure carries long-term measurable benefits to the growing number of patients with moderate to severe heart failure that are refractory to drugs.
|
|
| Status |
| Sunshine Heart announced in September 2008 that it had received Investigational Device Exemption (IDE) from the FDA to begin its first clinical feasibility trial for the C-Pulse device involving twenty patients in six university medical centers across the United States. The company could be the first to market with a Class III heart assist therapy. Additionally, Sunshine Heart listed on the Australian Stock Exchange in September 2004 and has a growing presence in Australia, New Zealand and the United States of America. The company has scheduled its first implant for January 2009. Sunshine Heart is currently pursuing venture capital, institutional investor awareness, M&A advisors, and strategic/corporate partners. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
